Add Yahoo as a preferred source to see more of our stories on Google. Novo Nordisk has received a warning letter from the US Food and Drug Administration (FDA) related to the company’s failure to ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...

Vídeo mostra novo ataque dos EUA a embarcação no Pacífico Mel Lisboa contrai IST em estado avançado e desabafa Por que invasão por terra no Irã pode estar a caminho — mas não por soldados americanos ...

Add Yahoo as a preferred source to see more of our stories on Google. Novo Nordisk files suit against telehealth provider Hims & Hers, alleging unauthorized versions of Ozempic and Wegovy. The case ...

A lawsuit that drugmaker Novo Nordisk filed on Monday against telehealth firm Hims & Hers shows how fierce the maneuvering over the booming obesity-drug market has become. In the lawsuit filed in a ...

Novo Nordisk conquered the world with its borderline miraculous drug semaglutide, sold as Ozempic and Wegovy. But with a sinking stock price and compelling alternatives eating its lunch, it’s now ...

LONDON, Feb 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him ...

Os Himbas não tomam banho durante toda a sua vida - ao menos não o banho que a gente conhece. Novo ataque americano contra o Irã pode ser ainda mais letal que o primeiro Rio bate recorde e tem lotação ...

During the first six months of Maziar Mike Doustdar's tenure as Novo Nordisk's CEO, the company enjoyed a run of positive momentum highlighted by the launch of its Wegovy pill and a recent stock-price ...

Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026. Got a confidential news tip? We want to ...